SCL Science

SCL Science Liabilities

The The Liabilities of SCL Science (246960.KQ) as of Oct 17, 2026 is 56.43 B KRW. In the previous year, The Liabilities was 8.54 B KRW — a change of 560.72% (higher).

Liabilities

56.43 BKRW

YoY

560.72%

Last updated:

In 2025, SCL Science's total liabilities amounted to 56.43 B KRW, a 560.72% difference from the 8.54 B KRW total liabilities in the previous year.

The SCL Science Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
1.66 B KRW
Jan 1, 2019
2.15 B KRW
Jan 1, 2020
4.41 B KRW
Jan 1, 2021
21.80 B KRW
Jan 1, 2022
17.77 B KRW
Jan 1, 2023
11.26 B KRW
Jan 1, 2024
8.54 B KRW
Jan 1, 2025
56.43 B KRW
The SCL Science Liabilities history
YEARLiabilitiesYoY
56.43 BKRW+560.72%
8.54 BKRW-24.12%
11.26 BKRW-36.66%
17.77 BKRW-18.50%
21.80 BKRW+394.60%
4.41 BKRW+105.02%
2.15 BKRW+29.66%
1.66 BKRW+49.76%
1.11 BKRW+15.60%
957.90 MKRW-93.32%
14.34 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing SCL Science's Liabilities

SCL Science's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating SCL Science's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing SCL Science's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

SCL Science's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in SCL Science’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about SCL Science stock

The Liabilities of SCL Science is 56.43 B KRW in 2025.

The Liabilities of SCL Science changed from 8.54 B KRW to 56.43 B KRW, representing a 560.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities SCL Science since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's SCL Science historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — SCL Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — SCL Science